Phase 1RecruitingNCT06731218
RGB-5088 islet cell injection in T1D
Hangzhou Reprogenix phase 1 study of RGB-5088 islet cell transplantation, assessing safety and early efficacy in adults with type 1 diabetes.
Primary endpoints
- Safety assessed by adverse events
- Proportion with HbA1c <= 6.5% and free of severe hypoglycemic events
Results so far
No results posted yet.